Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.
The lawsuit argues the manufacturer's use of "unfair practices has driven up equipment repair costs for farmers" and deprived farmers the ability to make timely repairs on critical farming critical.